secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2024-01-30T23:59:59+00:00
Accession:  0001724521-24-000034
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gilead invests $320M in Arcus at $21/share; collaboration amended to accelerate anti-TIGIT program
--------------------------------------------------------------------------------

- Gilead purchases 15.2M shares for $320M at $21/share, increasing ownership to 33%.
- Collaboration reprioritized: focus on Phase 3 STAR-121 (lung) and STAR-221 (GI); ARC-10 discontinued.
- New Phase 3 STAR-131 registrational study for domvanalimab + zimberelimab in lung cancer planned.
- Johanna Mercier (Gilead CCO) appointed to Arcus board; two prior Gilead designees resign.
- Quemliclustat pancreatic cancer study becomes Arcus-independent; cash runway extended into 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000172452124000034/0001724521-24-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000172452124000034/rcus-20240129.htm
  HTML page:      https://secwatch.observer/filing/0001724521-24-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer